Therefore, the creation of small-molecule drugs that target downstream signaling pathways and RAGE-ligand interactions holds enormous potential for translational research and the development of novel therapeutics for the treatment of RAGE-associated diseases, such as cancer, neurodegenerative diseases, chronic inflammatory conditions, and complications from diabetes. This evidence concerns the gene AGER and cancer.